Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Bergquist

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
CNS Neuroscience & Therapeutics|April 14, 2018
Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometryDongni Johansson, Anders Ericsson, Anders Johansson, et al.
NPJ Parkinson'S Disease|May 16, 2018
Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's diseasePer Odin, K Ray Chaudhuri, Jens Volkmann, et al.
Parkinsonism & Related Disorders|April 3, 2019
Evaluation of a sensor algorithm for motor state rating in Parkinson's diseaseDongni Johansson, Ilias Thomas, Anders Ericsson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 22, 2020
A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease DementiaPer Svenningsson, Per Odin, Nil Dizdar, et al.
European Journal of Clinical Pharmacology|January 20, 2017
Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessmentMarina Senek, Sten-Magnus Aquilonius, Håkan Askmark, et al.
Journal of Neurology|July 3, 2020
Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson's diseasePeter Hagell, Arja Höglund, Carina Hellqvist, et al.
Movement Disorders Clinical Practice|March 11, 2024
Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/FoscarbidopaK Ray Chaudhuri, Maurizio F Facheris, Bruno Bergmans, et al.
Journal of Neuroimmunology|April 8, 2017
Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignanciesRadu Constantinescu, David Krýsl, Kerstin Andrén, et al.
Computer Methods and Programs in Biomedicine|January 27, 2020
A multiple motion sensors index for motor state quantification in Parkinson's diseaseSomayeh Aghanavesi, Jerker Westin, Filip Bergquist, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 17, 2025
NLX-112 Randomized Phase 2A Trial: Safety, Tolerability, Anti-Dyskinetic, and Anti-Parkinsonian EfficacyPer Svenningsson, Per Odin, Filip Bergquist, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
CNS Neuroscience & Therapeutics|April 14, 2018
Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometryDongni Johansson, Anders Ericsson, Anders Johansson, et al.
NPJ Parkinson'S Disease|May 16, 2018
Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's diseasePer Odin, K Ray Chaudhuri, Jens Volkmann, et al.
Parkinsonism & Related Disorders|April 3, 2019
Evaluation of a sensor algorithm for motor state rating in Parkinson's diseaseDongni Johansson, Ilias Thomas, Anders Ericsson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 22, 2020
A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease DementiaPer Svenningsson, Per Odin, Nil Dizdar, et al.
European Journal of Clinical Pharmacology|January 20, 2017
Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessmentMarina Senek, Sten-Magnus Aquilonius, Håkan Askmark, et al.
Journal of Neurology|July 3, 2020
Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson's diseasePeter Hagell, Arja Höglund, Carina Hellqvist, et al.
Movement Disorders Clinical Practice|March 11, 2024
Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/FoscarbidopaK Ray Chaudhuri, Maurizio F Facheris, Bruno Bergmans, et al.
Journal of Neuroimmunology|April 8, 2017
Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignanciesRadu Constantinescu, David Krýsl, Kerstin Andrén, et al.
Computer Methods and Programs in Biomedicine|January 27, 2020
A multiple motion sensors index for motor state quantification in Parkinson's diseaseSomayeh Aghanavesi, Jerker Westin, Filip Bergquist, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 17, 2025
NLX-112 Randomized Phase 2A Trial: Safety, Tolerability, Anti-Dyskinetic, and Anti-Parkinsonian EfficacyPer Svenningsson, Per Odin, Filip Bergquist, et al.
Pageof 7